15.11.2022
Pharmasyntez became a winner of GхP-Profi 2022 International Innovation Competition
GxP-Profi 2022, industry competition organised by the Eurasian Academy of Good Practices together with the Ministry of Industry and Trade of Russia with the support of the Eurasian Economic Commission aims at identifying innovation leaders in the field of quality systems among manufacturers of medicines in the Eurasian Economic Union.
Pharmasyntez became the bronze medallist with its project “A set of engineering solutions to enable the production of medicines containing hazardous substances in accordance with current requirements”.
The company implemented a complex of engineering solutions in the shortest possible time, which coincided with the pandemic, having built from scratch one of the largest sites in Europe and still the only one in Russia at Pharmasyntez-Tyumen LLC, where state-of-the-art technologies are used to produce a wide range of hormonal medicines for hormone replacement therapy, oral contraception and treatment of gynaecological diseases associated with endocrine disorders. This was possible tanks to the assistance of the Ministry of Industry and Trade of Russia and the Government of the Tyumen Oblast. The plant is scheduled to be commissioned in the first quarter of 2023.
The award ceremony took place at the TASS press centre in the presence of Dmitry Galkin, Director of the Department of Pharmaceutical and Medical Industry Development, and Vladislav Shestakov, Director of the State Institute of Medicines and Good Practices, both under the Ministry of Industry and Trade of Russia.
The company implemented a complex of engineering solutions in the shortest possible time, which coincided with the pandemic, having built from scratch one of the largest sites in Europe and still the only one in Russia at Pharmasyntez-Tyumen LLC, where state-of-the-art technologies are used to produce a wide range of hormonal medicines for hormone replacement therapy, oral contraception and treatment of gynaecological diseases associated with endocrine disorders. This was possible tanks to the assistance of the Ministry of Industry and Trade of Russia and the Government of the Tyumen Oblast. The plant is scheduled to be commissioned in the first quarter of 2023.
The award ceremony took place at the TASS press centre in the presence of Dmitry Galkin, Director of the Department of Pharmaceutical and Medical Industry Development, and Vladislav Shestakov, Director of the State Institute of Medicines and Good Practices, both under the Ministry of Industry and Trade of Russia.
“The key feature of the project – as Oleg Astafurov, Vice President of Government Relations of the Pharmasyntez Group of Companies, explained at the TASS press conference – is that hormonal drugs are classified as hazardous substances. This circumstance requires the use of special engineering solutions, complex expensive process equipment, as well as a very advanced system of quality and safety assurance and control of the produced drugs, which restrained import substitution in this area during many years.”